Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
12 June 1980Website:
http://www.enzo.comNext earnings report:
13 December 2024Last dividends:
N/ANext dividends:
15 November 2024Price
after hours | Fri, 01 Nov 2024 20:00:14 GMTDividend
Analysts recommendations
Institutional Ownership
ENZ Latest News
Enzo Biochem's overall topline benefits from revenue growth in the majority of its geographic regions.
FARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal fourth quarter ended July 31, 2024 and the fiscal year ended July 31, 2024. The Company also announced that its board of directors had authorized a cash dividend of $0.10 per share of its common stock.
Enzo Biochem will pay $4.5 million to settle claims it failed to adequately safeguard personal and private health information of its patients, New York Attorney General Letitia James said on Tuedsay.
Enzo Biochem shareholders frustrated with lack of capital returns following Clinical Labs sale to Labcorp Holdings. Stock trading near historic lows, but potential for attractive returns with simplified Life Sciences division and strong CEO incentives. Valuation potential of $2.00-3.22/share with $35m net cash and $75-120m business value, pending resolution of legal issues and potential share buybacks.
Discover why Zacks rates Enzo Biochem as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore ENZ's notable revenue growth and financial health amid market challenges.
Enzo Biochem's (ENZ) overall topline benefits from revenue growth in the majority of its geographic regions.
FARMINGDALE, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal third quarter ended April 30, 2024.
Enzo Biochem is a microcap company with a $30 million revenue run-rate Life Sciences business and $78-$85 million in cash. The company is likely being prepared for sale, with interest from potential acquirers and activists controlling 30% of voting shares. Enzo's focus on generating positive cash flow and enhancing shareholder value could lead to significant improvement in Life Sciences results.
FARMINGDALE, NY, April 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo Biochem” or the “Company”), a leading biosciences and diagnostics company, today announced that its special meeting of shareholders (the “Special Meeting”) to consider and vote on a proposal to approve the sale (the “Asset Sale”) of substantially all the assets and assignment of certain liabilities of its clinical laboratory business to Laboratory Corporation of America Holdings, a Delaware corporation (“Labcorp”) and adopt the Asset Purchase Agreement, dated as of March 16, 2023 (as such agreement may be amended from time to time, the “Asset Purchase Agreement”), by and among the Company, Enzo Clinical Labs, Inc., a New York corporation and Labcorp will be held on May 22, 2023 at 9:00 a.m. Eastern Time.
What type of business is Enzo Biochem?
Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.
What sector is Enzo Biochem in?
Enzo Biochem is in the Healthcare sector
What industry is Enzo Biochem in?
Enzo Biochem is in the Diagnostics & Research industry
What country is Enzo Biochem from?
Enzo Biochem is headquartered in United States
When did Enzo Biochem go public?
Enzo Biochem initial public offering (IPO) was on 12 June 1980
What is Enzo Biochem website?
https://www.enzo.com
Is Enzo Biochem in the S&P 500?
No, Enzo Biochem is not included in the S&P 500 index
Is Enzo Biochem in the NASDAQ 100?
No, Enzo Biochem is not included in the NASDAQ 100 index
Is Enzo Biochem in the Dow Jones?
No, Enzo Biochem is not included in the Dow Jones index
When was Enzo Biochem the previous earnings report?
No data
When does Enzo Biochem earnings report?
The next expected earnings date for Enzo Biochem is 13 December 2024